U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT07602855) titled 'A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)' on May 15.
Brief Summary: This is an early-phase clinical study investigating a new combination treatment, Ris-Rez given with ivonescimab for adults with advanced solid cancers. The study aims to determine:
* What dose(s) of Ris-Rez given with ivonescimab is safe and what are the side effects?
* How does the body handle the drug(s)?
* What dose of Ris-Rez given with ivonescimab may work best and can improve the treatment of cancer?
Study Start Date: Sept. 08, 2026
Study Type: INTERVENTIONAL
Conditio...